|
|
Post by tmfbmf on Feb 17, 2021 20:31:22 GMT
We paid Gil a million dollars to leave and paid Hardy half a million to sue us. So glad the "good ol boys" on the board are finally looking out for us shareholders.
|
|
|
|
Post by CM kipper007 on Feb 18, 2021 0:19:12 GMT
We paid Gil a million dollars to leave and paid Hardy half a million to sue us. So glad the "good ol boys" on the board are finally looking out for us shareholders. He got paid a million to quit?? |
|
|
|
Post by tmfbmf on Feb 18, 2021 0:41:26 GMT
We paid Gil a million dollars to leave and paid Hardy half a million to sue us. So glad the "good ol boys" on the board are finally looking out for us shareholders. He got paid a million to quit?? Over $900k. I have a feeling it'll seem cheap compared to how much we give the incoming CEO. |
|
|
|
Post by lcd on Feb 18, 2021 14:59:32 GMT
I made the wrong call buying more shares around $2.70 this week. Should have waited longer to see the market's reaction. I am still green overall and optimistic the slide will reverse course.
|
|
|
|
Post by jamesjohnson12 on Feb 18, 2021 16:10:56 GMT
Same here, but I am not too worried. There are a handful of relatively big catalysts on the horizon that could happen at any time (hire CEO, Japan trials fully enrolled, new investor day, Japan trial results, partnership, etc). I will probably buy more if this continues to dip...
|
|
|
|
Post by CM kipper007 on Feb 18, 2021 22:32:43 GMT
I made the wrong call buying more shares around $2.70 this week. Should have waited longer to see the market's reaction. I am still green overall and optimistic the slide will reverse course. A few cents here or there wont make too much difference in the long run. We all know this will boom or bust. Just hoping for the boom!! |
|
|
|
Post by lcd on Feb 18, 2021 22:36:26 GMT
I made the wrong call buying more shares around $2.70 this week. Should have waited longer to see the market's reaction. I am still green overall and optimistic the slide will reverse course. A few cents here or there wont make too much difference in the long run. We all know this will boom or bust. Just hoping for the boom!! Definitely. There will be price fluctuations in the coming months, but this stock will be worth >$10 billion or <$100 million in a couple of years. |
|
|
|
Post by twenty2 on Feb 24, 2021 22:53:52 GMT
twenty2
|
|
|
|
Post by graham11 on Feb 26, 2021 0:15:57 GMT
Getting close to my 10 year ....hope this is the magical one
|
|
|
|
Post by jckrdu on Feb 26, 2021 2:12:51 GMT
Small gap in chart from $1.94 - $1.96.
I usually only add more when lower gaps fill, but I'm not sure that one will.
If XBI heads to $140, gap likely fills.
I added more today near close at $2.10.
Will likely add more if gap fills.
|
|
|
|
Post by avtech on Feb 26, 2021 10:31:58 GMT
Small gap in chart from $1.94 - $1.96. I usually only add more when lower gaps fill, but I'm not sure that one will. If XBI heads to $140, gap likely fills. I added more today near close at $2.10. Will likely add more if gap fills. Appreciate the info. |
|
|
|
Post by imz72 on Mar 1, 2021 11:43:01 GMT
|
|
|
|
Post by jckrdu on Mar 3, 2021 15:56:30 GMT
Small gap in chart from $1.94 - $1.96. I usually only add more when lower gaps fill, but I'm not sure that one will. If XBI heads to $140, gap likely fills. I added more today near close at $2.10. Will likely add more if gap fills. Appreciate the info. Gap filled. Added a little more in gap. |
|
pata
Junior Member
Posts: 52 
|
Post by pata on Mar 4, 2021 0:37:20 GMT
jckrdu,
How has Gil’s departure altered your investment thesis for ATHX?
Are there particular events that you had planned to hold until, that you think are now unlikely to materialize?
Thanks in advance for any insights you may choose to share.
|
|
|
|
Post by avtech on Mar 12, 2021 19:25:51 GMT
Gap filled. Added a little more in gap. Doubled down at $1.95 today. |
|
|
|
Post by jckrdu on Mar 14, 2021 21:42:33 GMT
jckrdu, How has Gil’s departure altered your investment thesis for ATHX? Are there particular events that you had planned to hold until, that you think are now unlikely to materialize? Thanks in advance for any insights you may choose to share. I was sad to see Gil go. He got Athx here. (With a Phase 3 SPA in U.S.) He got Helios here. (He had the vision to jump on Japan regen med law changes 7 years ago.) That said, Gil’s departure hasn’t changed my investment thesis. IMO, the cells work. Pivotal trials (2) in Japan just have to come somewhere near prior results. Plus... many trial modifications made to increase probability of success; larger trial, eliminated 36-48 hour window. Plus... bar is only “signs of efficacy” in those 2 pivotal trials in Japan. Imo, high probability that bar is easily met for Ards and/or stroke. Which means at least conditional approval in Japan for one or both. Which means Athx is undervalued at current market cap. Never can be certain of near-term events (i.e. how market reacts to data releases), but eventually Athx is heading higher, Imo. |
|
|
|
Post by graham11 on Mar 18, 2021 16:18:51 GMT
I was also sad to see Gil go ....... This was his baby and it is a shame that he will not be there (employed at Athersys) to see it come to fruition ....Get up every morning expecting to see confirmation out of Japan ...... Healios has be hiring a number of people on the expectation of approval ....and the news out of Ohio (stow) was good news as well
|
|
|
|
Post by tmfbmf on Mar 18, 2021 17:25:28 GMT
The ARDS trial in Japan has added, at most, 2 patients since August. Hardy is incredibly stupid to keep dragging this out. Flu season in Japan is over. I don't know why he doesn't end the trial with 29 instead of 30 pts. Maybe he wasn't being honest about how good the patients were doing? Or maybe they're doing so well that he thinks 1 more patient will make the difference between conditional and full approval?
On the bright side, Healios has had about 6 weeks to analyze data from the 5 Covid pts after their 6 month follow ups. I expect they pushed their earnings call back to next week in order to have this news out there. Hopefully, there were no lemons! And hopefully, the market will react as irrationally jubilant for us as they did for MESO and CYDY after their misleading headlines.
|
|
|
|
Post by imz72 on Mar 18, 2021 21:22:31 GMT
The ARDS trial in Japan has added, at most, 2 patients since August. Hardy is incredibly stupid to keep dragging this out. Flu season in Japan is over. I don't know why he doesn't end the trial with 29 instead of 30 pts. Maybe he wasn't being honest about how good the patients were doing? Or maybe they're doing so well that he thinks 1 more patient will make the difference between conditional and full approval? On the bright side, Healios has had about 6 weeks to analyze data from the 5 Covid pts after their 6 month follow ups. I expect they pushed their earnings call back to next week in order to have this news out there. Hopefully, there were no lemons! And hopefully, the market will react as irrationally jubilant for us as they did for MESO and CYDY after their misleading headlines. I guess Hardy had discussions with the PMDA and they told him they want the enrollment to be completed as designed. Of course he can end the trial anytime but if he seeks approval he'd better do what satisfies them. Healios had the Q4 2020 CC in February. Next Friday they will hold their annual shareholders' meeting. As far as I recall they always hold it in the last week of March and it's focused on formalities, so there is no reason to expect news (unless "this time it's different"). |
|
|
|
Post by tmfbmf on Mar 18, 2021 22:54:09 GMT
The ARDS trial in Japan has added, at most, 2 patients since August. Hardy is incredibly stupid to keep dragging this out. Flu season in Japan is over. I don't know why he doesn't end the trial with 29 instead of 30 pts. Maybe he wasn't being honest about how good the patients were doing? Or maybe they're doing so well that he thinks 1 more patient will make the difference between conditional and full approval? On the bright side, Healios has had about 6 weeks to analyze data from the 5 Covid pts after their 6 month follow ups. I expect they pushed their earnings call back to next week in order to have this news out there. Hopefully, there were no lemons! And hopefully, the market will react as irrationally jubilant for us as they did for MESO and CYDY after their misleading headlines. I guess Hardy had discussions with the PMDA and they told him they want the enrollment to be completed as designed. Of course he can end the trial anytime but if he seeks approval he'd better do what satisfies them. Healios had the Q4 2020 CC in February. Next Friday they will hold their annual shareholders' meeting. As far as I recall they always hold it in the last week of March and it's focused on formalities, so there is no reason to expect news (unless "this time it's different"). How do you know he had discussions with the PMDA about this? Did I miss that revelation? Or just speculation? Ok, thanks for the correction on the annual meeting. Still, Hardy needs something to talk about so why not top line data for the Covid pts? He shouldn't need more than 6 weeks to analyze data for 5 patients in an open label study. Hoping we hear something out of Japan next week. |
|
